Figure 3 IL-10 inhibits renal inflammatory gene expression and promotes renal CD163 expression after diabetic myocardial infarction (MI). (A) Study protocol schematic. STZ-induced diabetic mice underwent MI surgery and were randomly assigned to one of three MI treatment groups: vehicle control, IL-10, or combination of IL-10 and SnPP. Each treatment was administered at days 0, 1, 3, 5, and 7 after MI. Mice were sacrificed 3 days after MI for short-term assessments or on day 28 after MI for long-term assessments. Heart function was assessed on days 0, 7, and 28 days after MI with echocardiography. (B) IL-10 treatment had no significant effect on heart ejection fraction (EF) at the early time point (day 7) after MI, but significantly improved EF at the late timepoint (day 28) after MI. (C–E) Gene expression of IL-1B, MCP-1, and CD163 in kidney on day 3 after diabetic MI. (F) Gene expression of CD163 in kidney on day 28 after diabetic MI. Data (n=6 per group) represent mean±SEM and were compared by one-way analysis of variance followed by Tukey’s test. *p<0.05 vs sham, #p<0.05 vs MI+vehicle. BGT, blood glucose testing; DM, diabetes mellitus; IL-10, interleukin 10; MCP-1, monocyte chemoattractant protein-1; STZ, streptozotocin.